Immix Biopharma (IMMX)
(Delayed Data from NSDQ)
$2.05 USD
+0.01 (0.49%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $2.03 -0.02 (-0.98%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
IMMX 2.05 +0.01(0.49%)
Will IMMX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IMMX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMMX
What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing'
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down
IMMX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Immix Biopharma, Inc. (IMMX) Is a Great 'Buy the Bottom' Stock Now
Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy
Other News for IMMX
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
Immix Biopharma Shareholders Back Growth and Governance Changes
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024